UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): March 7, 2016
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-34566 | 75-2308816 |
| (State or other jurisdiction of | (Commission File No.) | (IRS Employer ID No.) |
| incorporation or organization) | ||
| 18th Floor, Jialong International Building |
| 19 Chaoyang Park Road |
| Chaoyang District, Beijing 100125 |
| People’s Republic of China |
(Address of Principal Executive Offices)
86-10-6598-3111
Registrant's telephone number, including area code
____________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
ITEM 7.01 REGULATION FD DISCLOSURE.
On March 7, 2016, China Biologic Products, Inc. (the “Company”) completed an offering (the “Offering”) of 4,257,000 shares of its common stock at a public offering price of $110.00 per share, less the underwriting discounts and commissions. In the Offering, certain selling stockholders sold 4,257,000 shares (including 387,000 shares sold pursuant to the full exercise by the underwriter of its option to purchase additional shares) to the underwriter. The Company did not sell any shares in the Offering and did not receive any proceeds from the sale of the common stock by the selling stockholders in the Offering.
The Offering was made pursuant to an automatically effective shelf registration statement filed with the Securities and Exchange Commission.
The information contained in this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 8, 2016 | CHINA BIOLOGIC PRODUCTS, INC. | |||
| By: | /s/ David (Xiaoying) Gao | |||
| David (Xiaoying) Gao | ||||
| Chief Executive Officer | ||||